Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowEditor’s note: Eli Lilly and Co.’s stock topped $1,000 per share on Wednesday, one day after this story was originally published. Shares closed Wednesday at $1,017.78, up 3% on the day.
Eli Lilly and Co.’s stock hit an all-time high and almost reached $1,000 per share on Tuesday in the wake of several significant deals and after it received fast-track regulatory review from the U.S. Food and Drug Administration for its highly anticipated weight-loss pill, orforglipron.
Shares of Lilly briefly climbed to $999.95 per share Tuesday afternoon before settling to a closing mark of $988.53, up 2.26% on the day. The Indianapolis-based drugmaker has seen its stock jump nearly 19% over the past month and 9% over the past week.
The increase pushed Lilly’s market capitalization to $937 billion.
Orforglipron review
Last week, Lilly experimental medication orforglipron received the FDA’s Commissioner’s National Priority Voucher, a pilot program for accelerated drug review for companies supporting national interests, according to the FDA.
Lilly previously said it plans to submit orforglipron to global regulatory authorities by the end of the year for the treatment of obesity. The company also said it plans to submit orforglipron for regulatory approval for the treatment of Type 2 diabetes in 2026.
Analysts predict orforglipron could rack up sales of $10 billion to $40 billion per year by the end of the decade.
White house agreement
Lilly announced last week an agreement with the U.S. government to expand access to obesity medications and reduce costs for patients on government insurance programs and those paying for the drugs out of pocket.
Under the deal with the Trump administration, as early as April 1, those on Medicare will pay no more than $50 a month for Zepbound, another Lilly weight-loss drug available in a multi-dose pen, and for orforglipron.
Patients not covered by Medicare who pay for their own obesity medications can use the LillyDirect self-pay pharmacy. Zepbound, for example, costs $299 per month for the lowest dose and $499 for other doses, a $50 discount from current prices.
In return, Lilly will receive three years of tariff relief and will not be subject to future pricing mandates, the company said in a Nov. 6 news release. Analysts expect the deal to give Lilly up to 40 million new customers in the United States.
Others deals
This week, Lilly signed a research and licensing deal worth up to $1.2 billion with Boston-based biotech SanegeneBio to develop and commercialize RNAi therapies for metabolic diseases. Lilly is making an undisclosed equity investment and upfront payment, while SanegeneBio is eligible to receive up to $1.2 billion in regulatory, development, discovery and commercial milestone payments.
SanegeneBio’s potential therapies are aimed at cardiometabolic conditions, autoimmune kidney diseases and obesity.
Also, this week, Lilly signed a partnership deal with New York City-based genetics medicine company MeiraGTx Holdings potentially worth more than $475 million.
MeiraGTx Holdings has. a pipeline of four late-stage clinical programs focusing on congenital blindness, retinitis pigmentosa, Parkinson’s disease and radiation-induced xerostomia (dry mouth).
MeiraGTx will get an upfront payment of $75 million and potentially $400 million or more in milestone payments. It could also receive tiered royalties on licensed products.
In one more deal this week, Cambridge, Massachussetts-based Insilico Medicine announced a research collaboration with Lilly in which “the two parties will combine Insilico’s state-of-the-art Pharma.AI platforms with Lilly’s development and disease expertise to jointly discover and advance innovative therapies.”
Insilico said it is eligible to receive more than $100 million, including an upfront payment, milestone payments, and tiered royalties on sales after commercialization of any resulting drug products.
Please enable JavaScript to view this content.
Great news for Indianapolis and Indiana!